Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.68 |
| ▸ | JAK2 | O60674 | 10/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | MERTK | Q12866 | 2/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320592 | 0.94 | SYK (0.69) | SYKJAK2AXLMERTK | |
| SCHEMBL14320671 | 0.88 | JAK2 (0.57) | SYKJAK2HTR2AHTR2C | |
| SCHEMBL14720030 | 0.81 | SYK (1.00) | SYKJAK2 | |
| SCHEMBL14320593 | 0.81 | SYK (0.59) | SYKJAK2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL29635075 | 0.80 | SYK (0.98) | SYKJAK2 | |
| Hydrochloric Acid SCHEMBL14716834 | 0.80 | SYK (0.98) | SYKJAK2 | |
| SCHEMBL14320666 | 0.80 | KDM1A (0.53) | SYKJAK2 | |
| SCHEMBL14320756 | 0.80 | ABCG2 (0.67) | SYKJAK2 | |
| SCHEMBL14320390 | 0.78 | ABCG2 (0.53) | SYKJAK2 | |
| SCHEMBL14320515 | 0.77 | SYK (0.52) | SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | SYK 11/4885JAK2 60/4885AXL 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.